JAK/STAT Signaling
Targets for JAK/STAT Signaling
Products for JAK/STAT Signaling
- Cat.No. Product Name Information
- GC38081 Theliatinib Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases. Anti-tumor activity.
- GC19361 TP-3654 TP-3654 is a second-generation Pim kinase inhibitor with Ki values of 5 and 42 nM for Pim-1 and Pim-3, respectively.
- GC17621 TPCA-1 A selective inhibitor of IKK2
- GC34215 Trastuzumab (Anti-Human HER2, Humanized Antibody) Trastuzumab (Anti-Human HER2, Humanized Antibody) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (Anti-Human HER2, Humanized Antibody) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
- GC32726 Tucatinib (Irbinitinib) Tucatinib (Irbinitinib) (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.
- GC34847 TX1-85-1 An ErbB3 inhibitor
- GC31668 TYK2-IN-2 TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC50s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively.
- GC32052 Tyk2-IN-3 Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC50 of 485 nM.
- GC31659 Tyk2-IN-4 (BMS-986165) Tyk2-IN-4 (BMS-986165) (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain.
- GC65387 Tyk2-IN-5 Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active Tyk2 inhibitor and targets the JH2 domain, with a Ki of 0.086 nM for Tyk2 JH2 and an IC50 of 25 nM for IFNα.
- GC37846 Tyk2-IN-7 Tyk2-IN-7 (Compound 48) is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.
- GC37847 Tyk2-IN-8 Tyk2-IN-8 (Compound 3) is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2.
- GC19364 Tyrphostin AG 528 Tyrphostin AG 528 is an inhibitor of EGFR and ErbB2 with IC50s of 4.9 and 2.1 uM, respectively.
- GC15271 Tyrphostin AG 879 HER2 inhibitor
- GC38125 Tyrphostin AG30 Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts.
- GC19368 Upadacitinib Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders.
- GC12249 Varlitinib (ARRY334543) Varlitinib (ARRY334543) (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.
- GN10282 Vitexicarpin (Casticin)
- GC67867 VVD-118313
- GC40761 VX-509 VX-509 is a selective inhibitor of Janus kinase 3 (JAK3) with a Ki value of 2.5 nM in enzyme assays and an IC50 value of 50-170 nM in cellular assays dependent on JAK3 activity with no measurable activity against other JAK isotypes.
-
GC70140
W1131
W1131 is an effective STAT3 inhibitor that can induce ferroptosis. W1131 inhibits cancer progression in gastric cancer subcutaneous xenograft models, organoid models, and PDX models. W1131 effectively reduces chemoresistance of cancer cells to 5-FU. W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation pathways including the IL6-JAK-STAT3 pathway and ferroptosis pathway.
- GC16000 WHI-P180 EGFR/Janus Kinase 3 inhibitor
- GC37933 WHI-P180 hydrochloride WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively.
-
GC15980
WP1066
An inhibitor of STAT3
- GC13213 WZ3146 Mutant EGFR inhibitor, potent and irreversible
- GC15494 WZ4002 Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent
- GC11250 WZ8040 EGFR T790M inhibitor,irreversible amd potent
- GC64891 YM-341619 YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC50 of 0.70 nM.
-
GC70164
Zalutumumab
Zalutumumab is a highly affinity pure human IgG1 monoclonal antibody that targets EGFR. Zalutumumab binds to domain III of the epidermal growth factor receptor, exerting its effects by blocking the binding of epidermal growth factor and interfering with the receptor's active conformation. The EC50 values for Zalutumumab with IgG and its Fab regions are 7 and 19 nM, respectively. Zalutumumab can be used in cancer research.
-
GC70165
Zanidatamab
Zanidatamab (ZW25) is a human bispecific monoclonal antibody targeting 2 different HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumor activity.
- GC33171 ZD-4190 ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.
-
GC70169
Zenocutuzumab
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody that contains two different Fab arms targeting the extracellular domains of HER2 and HER3.
- GC37971 ZM39923 ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.